Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Novartis
Novartis
Novartis gets FDA breakthrough therapy status for ligelizumab to treat chronic spontaneous urticaria
Novartis gets FDA breakthrough therapy status for ligelizumab to treat chronic spontaneous urticaria
Pharmaceutical Business Review
Novartis
breakthrough therapy
FDA
ligelizumab
chronic spontaneous urticaria
Flag link:
JPM: Novartis CMO Tsai on how the pandemic is changing the face of biopharma R&D, how pharma works
JPM: Novartis CMO Tsai on how the pandemic is changing the face of biopharma R&D, how pharma works
Fierce Biotech
JPMHC 2021
pandemic
Novartis
COVID-19
R&D
Flag link:
BeiGene, Novartis in pact to develop tislelizumab for cancer settings
BeiGene, Novartis in pact to develop tislelizumab for cancer settings
Seeking Alpha
Novartis
BeiGene
tiselizumab
cancer
drug development
Flag link:
Lilly, Amgen and more back advocacy group's push to double migraine research dollars
Lilly, Amgen and more back advocacy group's push to double migraine research dollars
Fierce Pharma
Eli Lilly
Amgen
migraines
Allergan
Novartis
Biohaven
Teva Pharmaceutical
Flag link:
FDA Refuses to Approve Novartis' $9.7 Billion Cholesterol Drug for Now
FDA Refuses to Approve Novartis' $9.7 Billion Cholesterol Drug for Now
Motley Fool
Novartis
FDA
cholesterol
inclisiran
complete response letter
Flag link:
Novartis acquires a small biotech and its trio of brain drugs
Novartis acquires a small biotech and its trio of brain drugs
BioPharma Dive
Novartis
M&A
Cadent
Neuroscience
Flag link:
Amgen and Novartis tap TV host to jump-start migraine conversations—and fuel understanding
Amgen and Novartis tap TV host to jump-start migraine conversations—and fuel understanding
Fierce Pharma
Aimovig
Amgen
Novartis
migraines
celebrity endorsements
Flag link:
Novartis' heart failure med Entresto wins FDA panel backing for bigger patient group—but just how much bigger?
Novartis' heart failure med Entresto wins FDA panel backing for bigger patient group—but just how much bigger?
Fierce Pharma
Novartis
Entresto
heart failure
heart failure with preserved ejection fraction
Flag link:
Roche's MS blockbuster Ocrevus, facing new Novartis competition, scores FDA nod for more-convenient infusion
Roche's MS blockbuster Ocrevus, facing new Novartis competition, scores FDA nod for more-convenient infusion
Fierce Pharma
Roche
Novartis
Kesimpta
Ocrevus
MS
multiple sclerosis
Flag link:
Novartis raises the temp on Eylea rivalry with head-to-head trial win for Beovu in diabetic macular edema
Novartis raises the temp on Eylea rivalry with head-to-head trial win for Beovu in diabetic macular edema
Endpoints
Regeneron
Eylea
Novartis
Beovu
diabetic macular edema
Flag link:
Novartis/Incyte draw blank with Jakafi in COVID-19
Novartis/Incyte draw blank with Jakafi in COVID-19
Pharmaforum
Novartis
Incyte
Jakafi
COVID-19
clinical trials
Flag link:
Novartis’ $9.7B PCSK9 drug nabs first OK — now comes the challenge of finding a market
Novartis’ $9.7B PCSK9 drug nabs first OK — now comes the challenge of finding a market
Endpoints
Europe
Novartis
PCSK9
inclisiran
Flag link:
SABCS: Novartis touts Kisqali's 5-year breast cancer survival, advantage over Pfizer's Ibrance
SABCS: Novartis touts Kisqali's 5-year breast cancer survival, advantage over Pfizer's Ibrance
Fierce Pharma
Novartis
Kisqali
breast cancer
SABCS
Flag link:
ASH20: Out to shake up CML once again, Novartis lays out head-to-head between third-gen Gleevec scion and Pfizer rival
ASH20: Out to shake up CML once again, Novartis lays out head-to-head between third-gen Gleevec scion and Pfizer rival
Endpoints
ASH2020
Novartis
CML
asciminib
Pfizer
Flag link:
Novartis signs ophthalmology AI deal with RetinAI
Novartis signs ophthalmology AI deal with RetinAI
Pharmaforum
Novartis
RetinAI
opthalmology
Flag link:
ASH: Novartis makes its Kymriah case in follicular lymphoma, but another Gilead showdown awaits
ASH: Novartis makes its Kymriah case in follicular lymphoma, but another Gilead showdown awaits
Fierce Pharma
ASH2020
Novartis
Kymriah
follicular lymphoma
clinical trials
Flag link:
Novartis’s big wager on RNAi approaches the finish line
Novartis’s big wager on RNAi approaches the finish line
EP Vantage
Novartis
RNAi
COVID-19
Leqvio
cholesterol
Flag link:
Novartis taps smartpatient for app to support wet AMD patients
Novartis taps smartpatient for app to support wet AMD patients
Pharmaforum
Novartis
wet age-related macular degeneration
digital therapeutics
MyTherapy
mobile apps
Flag link:
Novartis Inks $1.35 Billion Deal with Mesoblast for Remestemcel-L for COVID-19 ARDS
Novartis Inks $1.35 Billion Deal with Mesoblast for Remestemcel-L for COVID-19 ARDS
BioSpace
Novartis
Mesoblast
remestemcel-L
COVID-19
ARDS
clinical trials
Flag link:
FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar
FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar
Pharmaforum
Novartis
Genentech
Lucentis
biosimilars
Samsung Bioepis
Biogen
FDA
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »